Jefferies raises Haleon price target to 410p on margin strength
Jefferies raised its price target for Haleon to 410p from 400p, citing a 70 basis point margin beat in H1. Haleon reported 3.1% organic sales growth in Q2, with Oral Health and Pain Relief segments performing well. Shares rose 0.28% to 364.10p. Jefferies expects 5%+ growth in H2 to meet guidance.
How this was made
The 30-second read
Why it matters
The upgrade highlights the company's ability to improve profitability despite mixed product performance.
Market read
Analyst target raise provides a fresh catalyst for Haleon, potentially driving short‑term buying interest.
What to watch
Respiratory product decline and potential headwinds in the US flu season could offset gains.
Background
Haleon reported Q2 organic sales growth of 3.1% with a 70bp margin beat, prompting Jefferies to raise its target.
Ticker impact
Jefferies raised its price target for Haleon to 410p, citing a 70bp margin beat and strong Q2 sales.
Modest upside of 2‑3% over the next week.
Margin beat and higher target provide fresh catalyst; stock already up modestly on the news.
Market effects
Consumer health sector may see broader optimism as margin improvements signal pricing power.
European markets could benefit from Haleon's stronger UK/Europe performance.
Limited to Haleon but may influence peers like GSK and Johnson & Johnson.
Counterpoint
Margin beat may be temporary; growth concerns remain if investment in innovation lags.
Key entities
- companyHaleon plc
Consumer health company behind Sensodyne, Advil, etc.
- analystJefferies
Brokerage firm that raised the price target.
